Analysts’ Recent Ratings Updates for SiBone (SIBN)

A number of research firms have changed their ratings and price targets for SiBone (NASDAQ: SIBN):

• 11/3/2026 – SiBone had its price target lowered by Needham & Company LLC from $27.00 to $26.00. They now have a “buy” rating on the stock.
• 11/3/2026 – SiBone had its “market outperform” rating reaffirmed by Citigroup.
• 11/3/2026 – SiBone had its price target raised by UBS Group from $25.00 to $26.00. They now have a “buy” rating on the stock.
• 11/3/2026 – SiBone had its price target raised by TD Cowen from $20.00 to $23.00. They now have a “buy” rating on the stock.
• 10/14/2026 – SiBone had its price target raised by Truist Financial from $23.00 to $25.00. They now have a “buy” rating on the stock.

SiBone Price Performance

Shares of SiBone stock traded down $0.83 during trading on Thursday, hitting $24.11. The stock had a trading volume of 322,183 shares, compared to its average volume of 635,269. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.15 and a quick ratio of 7.55. The firm has a market cap of $1.07 billion, a P/E ratio of -77.79 and a beta of 0.64. The business has a fifty day moving average of $19.61 and a two-hundred day moving average of $16.52. SiBone has a fifty-two week low of $11.48 and a fifty-two week high of $25.92.

SiBone (NASDAQ:SIBN) last issued its quarterly earnings results on Monday, November 2nd. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.05. SiBone had a negative net margin of 6.20% and a negative return on equity of 7.62%. The firm had revenue of $55.70 million for the quarter, compared to analysts’ expectations of $55.31 million. On average, sell-side analysts expect that SiBone will post -0.40 earnings per share for the current fiscal year.

Insider Buying and Selling at SiBone

In related news, Director Jeffrey W. Dunn sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $20.89, for a total transaction of $417,800.00. Following the completion of the sale, the director directly owned 16,057 shares in the company, valued at approximately $335,430.73. This trade represents a 55.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Anshul Maheshwari sold 3,738 shares of SiBone stock in a transaction that occurred on Thursday, October 29th. The stock was sold at an average price of $22.50, for a total transaction of $84,105.00. Following the completion of the transaction, the insider owned 214,497 shares in the company, valued at approximately $4,826,182.50. This trade represents a 1.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 258,371 shares of company stock valued at $5,156,716 in the last ninety days. Company insiders own 4.00% of the company’s stock.

SI-BONE, Inc (NASDAQ: SIBN) is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.

Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures.